论文部分内容阅读
检测58例晚期卵巢上皮癌病人早期血清CA_(125)水平,连同其残留病变、年龄、肿瘤期别、活动状况、初次手术时伴有腹水及粘连等情况,分析它们的预后价值。第一疗程后及整个化疗初始化疗期间,CA_(125)对无病生存期和总生存期都是很有意义的预后因素。在第一疗程后,CA_(125)对无病生存期是非常显著的预后因素( P<0.0005)。在此期间, CA_(125)对生存期是显著的预后因素( P<0.005),但是,在多变量分析中,不包括活动状态(P<0.001)。把这些病人分为三个有统计学差别的预后组。在上限组,病人的CA_(125)水平高于450U/ml,中位生存期很短,为7个月;在下限组,病人的CA_(125)水平低于55U/ml,中
The serum CA 125 levels in early stage of patients with advanced epithelial ovarian cancer were detected. The prognosis of early stage ovarian cancer patients was analyzed with the residual disease, age, tumor stage, activity status, ascites and adhesions during initial operation. After the first course of treatment and throughout the initial chemotherapy, CA 125 is a significant prognostic factor for disease-free survival and overall survival. After the first course of treatment, CA 125 was a very significant prognostic factor for disease-free survival (P <0.0005). During this period, CA 125 was a significant prognostic factor for survival (p <0.005), however, multivariate analysis did not include activity status (p <0.001). These patients were divided into three statistically different prognosis groups. In the upper limit group, the CA 125 level was higher than 450 U / ml and the median survival time was very short for 7 months. In the lower limit group, the CA 125 level in patients was lower than 55 U / ml